Akebia Therapeutics Inc. buy Piper Sandler
Start price
31.05.23
/
50%
€0.92
Target price
31.05.24
-
Performance (%)
13.76%
End price
01.06.24
€1.05
Summary
This prediction ended on 01.06.24 with a price of €1.05. The prediction had a final performance of 13.76%. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Akebia Therapeutics Inc. | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
Comments by Piper_Sandler for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating.
Ratings data for AKBA provided by MarketBeat
In the thread Trading Akebia Therapeutics Inc.
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten